- Home
- LVS vs TAK Comparison
LVS vs TAK Comparison
Compare LVS & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVS | TAK |
|---|---|---|
| Founded | 1988 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 43.3B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVS | TAK |
|---|---|---|
| Price | $57.11 | $18.33 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $69.46 | N/A |
| AVG Volume (30 Days) | ★ 7.0M | 3.6M |
| Earning Date | 01-28-2026 | 01-29-2026 |
| Dividend Yield | 2.10% | ★ 2.86% |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 2.35 | 0.45 |
| Revenue | $13,017,000,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $6.59 | N/A |
| Revenue Next Year | $4.75 | $0.95 |
| P/E Ratio | ★ $24.32 | $41.07 |
| Revenue Growth | ★ 15.21 | N/A |
| 52 Week Low | $30.18 | $12.99 |
| 52 Week High | $70.46 | $18.50 |
Technical Indicators
Market Signals| Indicator | LVS | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 76.92 |
| Support Level | $56.00 | $17.58 |
| Resistance Level | $59.22 | $18.50 |
| Average True Range (ATR) | 2.02 | 0.21 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 52.23 | 92.25 |
Price Performance
Historical ComparisonAbout LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.